EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The GFAP/NfL ratio does not outperform NfL or GFAP in genetic frontotemporal dementia

Julie F. H. De Houwer, Elise G. Dopper, Renee van Buuren, Liset de Boer, Tine Swartenbroekx, Ana Rajicic, Aitana Sogorb‐Esteve, Arabella Bouzigues, Lucy L. Russell, Phoebe H. Foster, Eve Ferry‐Bolder, Raquel Sanchez‐Valle, Robert Laforce, Caroline Graff, Daniela Galimberti, Rik Vandenberghe, Alexandre de Mendonça, Giuseppe di Fede, Isabel Santana, Alexander Gerhard, Johannes Levin, Benedetta Nacmias, Markus Otto, Maxime Bertoux, Thibaud Lebouvier, Simon Ducharme, Chris R. Butler, Isabelle Le Ber, Elizabeth Finger, Maria Carmela Tartaglia, Mario Masellis, James B. Rowe, Matthis Synofzik, Fermin Moreno, Barbara Borroni, Henrik Zetterberg, Yolande A. L. Pijnenburg, Charlotte Teunissen, Lize C. Jiskoot, John C. van Swieten

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)

DOI: 10.1002/dad2.70483 ↗
AbstractBibliografische Angaben

Abstract

Abstract INTRODUCTION We investigated the diagnostic utility of the plasma glial fibrillary acidic protein (GFAP)/neurofilament light chain (NfL) ratio in genetic frontotemporal dementia (FTD) and compared its performance with GFAP and NfL alone. METHODS Baseline plasma samples were available from 391 pathogenic variant carriers and non‐carriers, with longitudinal samples (≥2) from 259 participants. Linear mixed‐effects models were used to assess baseline differences between clinical groups, longitudinal trajectories, and the ability of the GFAP/NfL ratio to discriminate underlying TAR DNA‐binding protein (TDP) versus tau pathology. RESULTS Baseline GFAP/NfL ratios differed across clinical groups; however, the ratio did not outperform GFAP or NfL alone in any clinically relevant comparison. No significant differences were observed between symptomatic carriers with underlying TDP versus tau pathology. DISCUSSION The GFAP/NfL ratio provides no added value over NfL alone as a diagnostic or susceptibility biomarker in genetic FTD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →